Stem Cell Derived Pancreatic Islet Cell Treatment Shows Promise for Type-I Diabetes Mellitus
Investigators from the University of Toronta released some early data of a Phase 1/2 clinical trial investigating the safety and early efficacy of VX-880 a stem cell derived pancreatic islet cell product. All 6 adult patients with Type-1 Diabetes Mellitus who underwent treatment with VX-880 showed restored insulin secretion, improved glucose control and either reduction or elimination of the need for insulin dosing. Two patients with 12 months follow-up were insulin independent and no longer met criteria for Diabetes Mellitus.
Search our Directory
AABRM Members are not only experts in regenerative medicine but offer a wide range of related products, services and related-procedures in that field. Search our extensive Member Directory to find a Member near you.Member Directory